Help bring pragmatic trials, shared results, and more treatment options to patients in North Dakota.
Question 1 of 3
Pragmatic trials compare treatments during routine care. Participation remains voluntary and requires informed consent and appropriate safety oversight.
Right to Try has been federal law in North Dakota since 2018. It lets some patients ask manufacturers for experimental treatments—but it built no clinics, pays no providers, and publishes no results.
Federal Right to Try ActAbout 70,000 of North Dakota's 800,000 people live with a rare disease—and 95% of the roughly 7,000 rare diseases have no approved treatment to try.
GAO rare disease reportMontana licensed experimental treatment centers with SB 535. Right to Trial adds the evidence half—pragmatic trials, provider payment, and published results. North Dakota can adopt both at once.
Read the model actPatient estimate: North Dakota's share of the roughly 30 million Americans with a rare disease (GAO 2025), using Census 2025 population estimates.
Today's medicine manages these conditions. It cures none of them.
Estimates: national counts scaled to North Dakota's share of the US population (Census 2025). Each condition links to its national source.